Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by Sqidmandonon Sep 11, 2020 4:21pm
238 Views
Post# 31544604

A lot of Bull on the Bullboard

A lot of Bull on the Bullboard

All -

its time to get real regarding this stock.  First, let me assure you I own much more than 50k shares and am under water.  Have been for almost 3.5 years, as Ive accumulated on the way down.  But its time that we stop saying the analysts are all dumb, and we are the only ones who know.  Quite frankly, the fact that so few people (on this message board) own so much of the company is bad and frightening thing - we are all talking to ourselves, convincing ourselves, and resorting to posts about how to counteract short-selling - how is that a strategy!  We have people posting that even though Therf said Phase 3, the haven't satisfied phase 2 protocols.  And we've been anticipating this fantastic announcement for months, waiting til after Labor Day, and then it comes - and the stock ended lower today than it started yesterday before the announcement. This is about the third or fourth time the "big announcement" has come and gone - with a lower stock price.

There is no momentum for this small cap stock in a world that is paying attention to so many other things  - in the meantime the IR person has had ZERO impact (no new coverage), and the CEO has had no impact as well.  I for one will wait for three months (at most) to see if they do get the phase 3 passed by the FDA - I don't have much to lose at this point - but if this company gets to $4.00 im out - there is no reason to hold a small cap Biotech when you can get better returns in Apple, Amazon, Google and Facebook with safety and security. When I think about the opportunity cost over the last three years, I want to throw up.

I'd love for any one on this board to challenge me - tell me what is positive right now.  Why would you come out and say you intend to go general NASH - Phase 3 without having it nailed?  only to increase the stock price base for when the announcement that you have sign off comes out.  instead, the stock drops.  This is what happens with small, undercapitalized companies. why would you think this company has credibility?  they couldnt size the market before, and when an analyst called bullshit, everyone scoffed - except that "dumb" analyst was right - the market was way smaller for HIV indication than anticiapted.  Why did a "dumb" analyst know this, but no one here, or at the company know it?

You should all do yourselves a favor - try and figure out why the other NASH companies are covered, and THERF is not.  Try and figure out what they have, that THERF does not.  Stop talking to yourselves and convicning yourself that there is a great story that doesn't exist. Figure out the real story - beacuse the one thats getting floated holds no water.

Bullboard Posts